標(biāo)題: Titlebook: Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases; Christopher L. Cioffi Book 2020 Springer Nature Switzerlan [打印本頁] 作者: INFER 時間: 2025-3-21 17:52
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases影響因子(影響力)
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases影響因子(影響力)學(xué)科排名
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases網(wǎng)絡(luò)公開度
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases被引頻次
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases被引頻次學(xué)科排名
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases年度引用
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases年度引用學(xué)科排名
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases讀者反饋
書目名稱Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases讀者反饋學(xué)科排名
作者: 解開 時間: 2025-3-21 22:25
978-3-030-56621-0Springer Nature Switzerland AG 2020作者: 剝皮 時間: 2025-3-22 03:24 作者: 不自然 時間: 2025-3-22 05:47 作者: ureter 時間: 2025-3-22 09:52 作者: 無能力 時間: 2025-3-22 14:04
https://doi.org/10.1007/978-3-662-36243-3o major clinical presentations of AMD: atrophic or “dry” and neovascular or “wet.” Geographic atrophy (GA) is the most severe manifestation of dry AMD which represents the form of the disease characterized by the highest prevalence. A smaller fraction of AMD patients (10–20%) develop choroidal neova作者: 無能力 時間: 2025-3-22 17:03 作者: 殺蟲劑 時間: 2025-3-22 22:18 作者: 一起平行 時間: 2025-3-23 04:21
https://doi.org/10.1007/978-3-662-36243-3but the number of clinical gene therapy trials has been very limited. The improved visual function outcomes in individuals affected by retinal dystrophy caused by biallelic variants in the RPE65 gene after gene therapy treatment contributed to the US Food and Drug Administration (FDA) and European M作者: CARE 時間: 2025-3-23 06:25 作者: 心胸狹窄 時間: 2025-3-23 12:00
Topics in Medicinal Chemistryhttp://image.papertrans.cn/e/image/283037.jpg作者: gerontocracy 時間: 2025-3-23 15:46
Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases978-3-030-56619-7Series ISSN 1862-2461 Series E-ISSN 1862-247X 作者: 多樣 時間: 2025-3-23 22:03
1862-2461 re therapeutic opportunities for age-related macular degener.This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited R作者: 不整齊 時間: 2025-3-24 00:00
Book 2020ed Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases..Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected t作者: hypnotic 時間: 2025-3-24 02:33 作者: 單片眼鏡 時間: 2025-3-24 08:49 作者: stratum-corneum 時間: 2025-3-24 13:45
https://doi.org/10.1007/978-3-662-36243-3ts; (2) new and emerging therapies for primary open angle glaucoma (POAG) in both the clinical and pre-clinical stages (the review of emerging glaucoma therapies highlighted in this chapter is limited to those for which in vivo efficacy data were published); and (3) progress toward treating the underlying optic neuropathy, which defines glaucoma.作者: CHASE 時間: 2025-3-24 15:52 作者: 伸展 時間: 2025-3-24 21:08 作者: 獨(dú)白 時間: 2025-3-25 01:23
Emerging Therapeutic Modalities for Diabetic Retinopathy,to improve tissue penetration and cell selectivity. We report here on selected novel ocular drug delivery technologies and therapeutic modalities, and their potential as game-changing clinical approaches for addressing the sight-threatening complications of diabetes.作者: malapropism 時間: 2025-3-25 03:46
Introduction: Overview of the Human Eye, Mammalian Retina, and the Retinoid Visual Cycle,x anatomy has evolved to effectively focus incoming light from the surrounding environment and to harness its energy by efficiently utilizing the physicochemical properties of retinoids. This remarkable organ is capable of phototransduction, which involves the conversion of photon energy into an int作者: 富饒 時間: 2025-3-25 08:00
Ocular Pharmacokinetics and Drug Delivery Challenges,eakdown of the blood-retinal barrier or complications of neovascularization, two consequences of angiogenesis. These pathophysiologic processes are driven by chemokines and cytokines (particularly vascular endothelial growth factor (VEGF)), which are upregulated by vascular and inflammatory damage t作者: 徹底檢查 時間: 2025-3-25 13:20 作者: 兵團(tuán) 時間: 2025-3-25 17:34 作者: BARGE 時間: 2025-3-25 23:33 作者: 悲痛 時間: 2025-3-26 02:28
Recent Developments for the Treatment of Glaucoma,umber growing to over 110 million in 2040. The prevalence of glaucoma coupled with the unfortunate reality that the disease still progresses in 30–80% of patients prescribed the standard of care has led to continued interest in glaucoma drug discovery. This chapter reviews advances in glaucoma thera作者: amorphous 時間: 2025-3-26 06:46
Emerging Gene Therapy Approaches Under Clinical Investigation for Retinal Degenerative Diseases,but the number of clinical gene therapy trials has been very limited. The improved visual function outcomes in individuals affected by retinal dystrophy caused by biallelic variants in the RPE65 gene after gene therapy treatment contributed to the US Food and Drug Administration (FDA) and European M作者: 車床 時間: 2025-3-26 09:00 作者: 平 時間: 2025-3-26 16:15 作者: modest 時間: 2025-3-26 18:15 作者: 共棲 時間: 2025-3-26 20:57
https://doi.org/10.1007/978-3-662-36243-3are converted into photosensitive cells. The majority of the current trials utilize a viral vector delivered into the subretinal space or into the vitreous cavity in order to express a specific gene. Other treatment options are targeting the mechanism of the retinal degeneration. This chapter is a r作者: paleolithic 時間: 2025-3-27 01:35 作者: 會犯錯誤 時間: 2025-3-27 07:10 作者: CAPE 時間: 2025-3-27 10:02
Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Dimproving or maintaining visual acuity in CNV patients over long periods of time. The work on the new generation of anti-VEGF agents with higher potency and long-lasting efficacy is ongoing with the goal of reducing the frequency of intravitreal injections required for achieving good visual acuity o作者: Feature 時間: 2025-3-27 15:48
Emerging Gene Therapy Approaches Under Clinical Investigation for Retinal Degenerative Diseases,are converted into photosensitive cells. The majority of the current trials utilize a viral vector delivered into the subretinal space or into the vitreous cavity in order to express a specific gene. Other treatment options are targeting the mechanism of the retinal degeneration. This chapter is a r作者: 打谷工具 時間: 2025-3-27 19:59 作者: scotoma 時間: 2025-3-28 00:48 作者: mydriatic 時間: 2025-3-28 05:26
1862-2461 eatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy..978-3-030-56621-0978-3-030-56619-7Series ISSN 1862-2461 Series E-ISSN 1862-247X 作者: cardiovascular 時間: 2025-3-28 09:07
10樓作者: excrete 時間: 2025-3-28 11:00
10樓
